Clinical trials: Trypanosomiasis, African
Trypanosomiasis, African
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
This trial will study the tolerability and pharmacokinetic of fexinidazole using two different dosage regimen of repeated administrations.
- Trial name
- NCT01483170
- Testing
- Tablets Fexinidazole
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis, Human African Trypanosomiasis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Tropical fevers have been a diagnostic challenge from the antiquity. Nowadays, despite the availability of good diagnostic capacities, undifferentiated febrile illnesses continue to be a thorny problem for travel physicians.
- Conditions
- Visceral Leishmaniasis, Human African Trypanosomiasis, Enteric Fever, Melioidosis
- Trial name
- NCT01766830
- Testing
- rk28 ICT, IT LEISH (rK39), Immunochromatographic HAT test
- Where
- 7 sites in Cambodia, Democratic Republic of the Congo and 2 more
- Volunteers
- 1,927 people
- Sponsor
- University Hospital, Geneva
Trypanosomiasis, African
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
The purpose of this study is to compare the therapeutic combination of I.V. eflornithine + oral nifurtimox to the standard IV eflornithine regimen in terms of therapeutic efficacy and clinical safety, in patients suffering from…
- Trial name
- NCT00146627
- Testing
- Eflornithine, Nifurtimox
- Where
- 4 sites in Democratic Republic of the Congo, Republic of the Congo
- Volunteers
- 280 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
Phase 1 bioequivalence (BE) study. This study is for regulatory purpose to determine BE of the tablet formulation used in the clinical trials and the final marketed tablet formulation under fed condition.
- Trial name
- NCT02571062
- Testing
- Fexinidazole
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, Trypanosomiasis, African
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
This study is aimed at assessing the tolerability and pharmacokinetic parameters of SCYX-7158 in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, SCYX-7158 shows highly…
- Conditions
- Trypanosomiasis, Trypanosomiasis, African, Protozoan Infections, Parasitic Diseases
- Trial name
- NCT01533961
- Testing
- SCYX-7158
- Where
- 2 sites in France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
Multicenter, open label, uncontrolled phase IIIb study of therapeutic use of the combination of nifurtimox and eflornithine (NECT) for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the…
- Trial name
- NECT-FIELD (NCT00906880)
- Testing
- Nifurtimox-Eflronithine Combination Treatment (NECT)
- Where
- 6 sites in Republic of the Congo
- Volunteers
- 630 people
- Sponsor
- Drugs for Neglected Diseases
African Trypanosomiasis
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers.
- Trial name
- NCT00803933
- Testing
- DB289, Pentamidine
- Where
- 2 sites in Republic of the Congo
- Volunteers
- 111 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Trypanosomiasis, African
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers.
- Trial name
- NCT00802594
- Testing
- DB289
- Where
- 2 sites in Angola, Republic of the Congo
- Volunteers
- 30 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Trypanosomiasis, African
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda, in which the combination of eflornithine + nifurtimox showed very promising efficacy and safety.
- Trial name
- NECS (NCT00489658)
- Testing
- Eflornithine plus Nifurtimox combination therapy
- Where
- Uganda
- Volunteers
- 31 people
- Sponsor
- Epicentre
Trypanosomiasis, African
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
The treatment human African trypanosomiasis (HAT) in the meningoencephalitic phase relies on two molecules officially registered: melarsoprol, the most commonly used, has a poor safety profile and is becoming ineffective due to…
- Trial name
- NCT00330148
- Testing
- melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d, melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d, nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
- Where
- Uganda
- Volunteers
- 435 people
- Sponsor
- Epicentre